Brokerages Set Marker Therapeutics, Inc. (NASDAQ:MRKR) PT at $10.17

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $10.1667.

MRKR has been the subject of several recent analyst reports. HC Wainwright began coverage on Marker Therapeutics in a research note on Monday, December 8th. They set a “buy” rating and a $10.00 target price for the company. Wall Street Zen upgraded shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Marker Therapeutics in a report on Monday, December 22nd. Finally, Zacks Research downgraded shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th.

Hedge Funds Weigh In On Marker Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Boyer Financial Services Inc. acquired a new stake in shares of Marker Therapeutics during the 4th quarter worth approximately $57,000. Two Sigma Investments LP acquired a new position in shares of Marker Therapeutics in the 3rd quarter valued at $33,000. Virtu Financial LLC bought a new position in shares of Marker Therapeutics during the 3rd quarter worth about $25,000. Finally, Jane Street Group LLC acquired a new stake in shares of Marker Therapeutics during the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 22.39% of the company’s stock.

Marker Therapeutics Trading Down 0.6%

NASDAQ MRKR opened at $1.65 on Tuesday. Marker Therapeutics has a 1 year low of $0.81 and a 1 year high of $4.07. The company has a fifty day simple moving average of $1.62 and a 200 day simple moving average of $1.26. The company has a market cap of $27.51 million, a P/E ratio of -1.34 and a beta of 1.44.

Marker Therapeutics (NASDAQ:MRKR) last released its earnings results on Thursday, November 13th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.57. The firm had revenue of $1.23 million during the quarter, compared to analyst estimates of $0.72 million. Marker Therapeutics had a negative net margin of 304.56% and a negative return on equity of 92.35%. Equities research analysts forecast that Marker Therapeutics will post -0.65 EPS for the current fiscal year.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.